Living with treatment-resistant depression can leave you tired in a very particular way. You may have tried, waited, hoped and then had to start again. If you are searching for how esketamine works, you may be looking for clear information that does not ask you to become a scientist or pretend this is easy.
SPRAVATO® (esketamine) nasal spray works differently from many traditional antidepressants because it affects glutamate signaling, a communication system involved in how brain networks adapt. For some people, that different pathway may help explain why changes can show up within hours or days rather than weeks.
This article can help you understand the science in plain language. It cannot tell you whether SPRAVATO is right for your medical history, risks and goals. That conversation belongs with a qualified clinician who can look at the whole of your life.
Key Terms for Understanding SPRAVATO
Ketamine vs. esketamine vs. SPRAVATO: Ketamine is an older medication used in anesthesia and pain settings. Esketamine is the S-enantiomer of ketamine, meaning one of two mirror-image molecular forms. SPRAVATO is the FDA-approved brand of esketamine given as an intranasal medicine in certified settings.
NMDA receptor: A receptor involved in how brain cells communicate through glutamate. It helps regulate signal flow and plasticity.
Glutamate: A major messenger chemical in the brain linked to learning, connectivity and neural “traffic” between circuits.
AMPA receptor: Another glutamate receptor that helps strengthen and stabilize communication between neurons.
BDNF: Brain-derived neurotrophic factor, a protein that supports the survival, growth and maintenance of neurons and helps regulate synaptic plasticity.
Synaptogenesis and neuroplasticity: Processes that help form and strengthen connections between neurons, which can influence how brain networks function over time.
Rapid-acting antidepressant: A medication that can lead to noticeable symptom changes for some people within hours or days. Rapid does not mean guaranteed, but it does mean the timeline can look different from what you may have experienced before.
Treatment-resistant depression (TRD): Depression that has not improved enough after adequate trials of at least two standard treatments. You may also see it written as TRD.
What SPRAVATO Is and How It Relates to Ketamine
Esketamine is chemically related to ketamine, a medication long used in anesthesia and pain care. For depression treatment, the main point is not the history of ketamine. The main point is that esketamine acts on a different set of brain pathways than many first-line antidepressant medications.
SPRAVATO is an antidepressant option used in care pathways for TRD, and it is given with clinical oversight. Because it is delivered as an esketamine nasal spray rather than a daily pill, the experience and timing can feel different.
At Memor Health, we find that people often feel steadier when they understand what a medication is doing in the brain. Clear information does not remove every worry, but it can make the next conversation with your care team feel less intimidating.
Some molecules come in two mirror-image forms, like left and right hands. These are called enantiomers. They can interact with receptors in slightly different ways.
That is why esketamine is often discussed at the receptor level. Small chemical differences can change how a molecule fits into a receptor system and what sequence of signals follows.
Researchers are still mapping the full story, but the leading model follows a chain: NMDA receptor effects, a change in glutamate signaling, greater AMPA receptor activity, downstream BDNF-related signaling and neuroplasticity. Picture it as a sequence, not a single switch.
NMDA Receptor Antagonism: A Brake Eases
Esketamine is an NMDA receptor antagonist. In plain language, it partially blocks one kind of receptor involved in brain signaling. Many models focus on NMDA receptors on inhibitory interneurons, where that block can change downstream firing patterns.
A simpler way to picture it: imagine traffic lights slowing activity at a busy intersection. Esketamine affects one part of that traffic system, so signals may briefly reroute.
Glutamate Surge: A Short Burst of Signal
After NMDA blockade, many models describe increased glutamatergic transmission. The size and location of that effect can vary by circuit and by person.
For you, the useful picture is this: when the brake eases, a brief wave of messages can move through the network, like a quick pulse of communication.
AMPA Activation: Signals Get Received Differently
If glutamate is the message, AMPA receptors are part of how that message gets received and acted on. More AMPA activity can strengthen the way signals move between neurons.
Preclinical work links increased AMPA receptor activation with antidepressant-like effects. Researchers often call this the AMPA throughput idea, but you do not need that phrase to understand the point: the message may travel through the system in a way that helps brain networks respond differently.
Downstream BDNF Signaling: Growth Support Comes Online
Glutamate-AMPA signaling can trigger intracellular cascades that influence synaptic proteins and BDNF-related pathways. Human biomarkers remain an active area of research.
In gentler language, the brain may begin releasing support tools that help connections stabilize and reorganize.
Synaptogenesis and Neuroplasticity: New Connections, New Options
The neuroplasticity model suggests changes in synaptic density and function in key mood networks, which can support recovery. This does not guarantee repair or promise a specific outcome, but it offers a hopeful way to understand what may be happening biologically.
Think of a city adding and strengthening side roads. The old roads are not erased, but there may be more routes out of gridlock.
Animal studies, human neuroimaging and clinical observations support mechanism summaries like this. The broad direction remains consistent: NMDA modulation influences glutamate signaling, and that may shift synaptic function faster than monoamine-only approaches.
For a regulatory view of mechanism and safety framing, you can read the SPRAVATO prescribing information.
How Does Esketamine Work in the Glutamate System?
Glutamate is the brain’s primary excitatory messenger. It plays a role in learning, memory and how networks coordinate emotion and attention. When glutamate signaling is dysregulated, circuits can become rigid, noisy or disconnected. That kind of disruption can be associated with depressive symptoms like slowed thinking, rumination and reduced motivation.
Many traditional antidepressants focus on monoamines like serotonin and norepinephrine. SSRIs and SNRIs may indirectly influence plasticity, but they begin by adjusting reuptake and downstream receptor signaling over time. Esketamine takes a more direct route into glutamatergic signaling, which may help explain why the timeline can feel different for some people.
That does not make one approach better than another. It means the entry point into brain chemistry is different, and that difference matters when you are trying to understand timing, side effects and the first changes you may notice.
Why the Nasal Spray Route Matters: Delivery, Timing and Pharmacokinetics
A nasal spray is not just about convenience. Intranasal delivery changes how a medication is absorbed. Instead of moving through the digestive system first, intranasal medicines can be absorbed through nasal tissues into the bloodstream relatively quickly.
With esketamine nasal spray, this can translate into a faster rise in blood levels than many oral medications. Pharmacokinetics still varies from person to person. Fast does not mean instant, but the route supports a different timing profile.
Because short-term effects can include changes in perception and alertness, SPRAVATO is given in a monitored clinical setting. That structure is not about making care harder to access. It is about keeping you safe during the window when the medicine is most active.
For oversight requirements, the FDA outlines the SPRAVATO REMS program.
Why You Are Observed After Dosing
Observation is tied to how the brain and body can respond in the short term. Some effects are linked to shifts in NMDA-related signaling, and others are linked to how the body processes the medication.
Clinicians monitor for three broad categories: dissociation or perceptual changes, sedation-like effects and blood pressure changes. These effects are often time-limited and tend to cluster around the dosing session.
Monitoring also protects you in practical ways. If attention, balance or perception is altered, you need a calm place to be watched until you are back to baseline.
Why Effects Can Feel Fast and What “Rapid-Acting” Means
When you hear rapid-acting, you may picture a dramatic shift that arrives all at once. The clinical reality is more careful than that. Rapid-acting means some people notice meaningful changes within hours or days. It does not mean everyone responds quickly or completely.
The biological reason relates to synaptic signaling. The NMDA-to-glutamate-to-AMPA cascade can influence network function sooner than pathways that rely on slower receptor adaptations. For some people, that shift may feel like less mental stuckness, less emotional pressure or a softer edge to rumination.
Responses vary. Some people feel little at first and notice gradual change later. Some feel a clear shift, then have uneven weeks. Your nervous system, stress load, sleep and co-occurring anxiety can all shape what fast feels like in your body.
What Changes People May Notice First vs. Later
Early changes, when they happen, often show up in mental process rather than immediate joy or motivation. You might notice less looping, a little more mental space or a slightly easier time starting basic tasks.
Mood improvements and functional gains can lag behind those early signs. That can feel confusing if you expected a clear happier signal. Tracking helps because subtle cognitive changes can come before broader recovery markers.
Your clinician may ask you to look at patterns across days, not minutes. The goal is to understand the trajectory, not judge one session as a success or failure.
What Clinical Evidence Shows for Treatment-Resistant Depression
SPRAVATO was approved by the FDA for treatment-resistant depression as monotherapy or in conjunction with an oral antidepressant, with use restricted to certified settings under a risk management program. The FDA announcement, written for the public, is available at FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic.
Evidence includes randomized controlled trials in adults with TRD, often evaluating esketamine plus an oral antidepressant compared with placebo plus an oral antidepressant. Researchers measure symptom severity scores over time and look at response and remission rates at the group level.
Maintenance research also matters in TRD because relapse prevention is part of real-world care. A notable randomized withdrawal design evaluated ongoing use to reduce relapse risk in responders, which speaks to durability for some patients rather than certainty for every person.
For peer-reviewed trial context, see the relapse-prevention study Esketamine nasal spray in treatment-resistant depression.
Evidence still has limits. Trial populations have inclusion criteria. Real-world patients bring complexity. Responses are not uniform. That is why clinicians talk about expected benefits as probabilities, not promises.
What FDA Approval Does and Does Not Mean
FDA approval means the agency determined that, for the indicated population and required conditions, the benefits outweighed the risks based on the submitted data. It also means expectations for labeling, monitoring and post-marketing surveillance are formalized.
Approval does not mean a medication will work for you or that side effects will be mild. It does not remove the need for careful screening, monitoring and ongoing assessment of whether the plan still fits your life.
If you are reading studies, ask your clinician how closely the study population matches your history, including prior medication trials, co-occurring conditions and current stressors.
What This Mechanism Can Mean for the Brain Over Time
Neuroplasticity can sound abstract, but the practical idea is simple: the brain can adapt. When depression has been entrenched, circuits can become narrow in their responses. Your mind may feel like it returns to one track no matter how hard you try to redirect it.
Synaptogenesis and BDNF are often described as creating conditions for new patterns. That does not mean instant personality change. It can mean your brain has more capacity to learn new responses, tolerate emotions without shutting down and shift attention away from threat loops.
This is where whole-person care matters. Biology can open a window, but your day-to-day inputs help determine what happens during that window.
Sleep regularity, movement, nutrition, stress practices, therapy and supportive relationships can reinforce new learning. That reinforcement can matter when you are practicing skills for rumination, avoidance, trauma responses or emotional regulation.
A Realistic Way to Pair Biology With Support
When symptoms ease even a little, many people describe having more bandwidth. That bandwidth can make therapy feel more usable, routines more possible and relationships easier to enter instead of avoid.
That can be a grounded way to think about esketamine treatment. It is not a standalone fix. It is a biological shift that may support other forms of care you are already doing or want to begin.
Collaborative planning helps. Your clinician can align medication goals with therapy goals, sleep goals and the realities of your home and work life.
Safety and Monitoring: Common Short-Term Effects and Why Clinicians Watch Closely
Short-term effects often reflect the same systems tied to the mechanism and delivery route. Dissociation or perceptual changes can occur, ranging from mild detachment to stronger changes in how time or surroundings feel.
People also report dizziness, nausea, fatigue and temporary increases in blood pressure. Monitoring is built into the care model so clinicians can check on you until acute effects resolve.
If you feel suicidal or at immediate risk of harm, seek urgent help right away. In the US, you can call or text 988 to reach the 988 Suicide & Crisis Lifeline.
This section is not a complete safety guide, and it is not a substitute for personalized medical advice. Your clinician should review risks, interactions and safety steps based on your history.
How Side Effects Relate to Timing and Dose Sessions
Many side effects cluster around the dosing session because blood levels rise and fall over a short window. That time-linked pattern is one reason observation periods exist.
If side effects feel intense or linger longer than expected, tell your clinician. Plans can be adjusted, and monitoring decisions are made around safety, not convenience.
Avoid driving or high-risk tasks until your care team confirms you are safe to resume them after sessions.
Who This Information Is For
This page is for people trying to understand the mechanism of SPRAVATO in the context of treatment-resistant depression. It is also for family members who want a clearer picture of what glutamate-based treatment means.
Reading about the mechanism can help you ask better questions, track changes more clearly and feel calmer in conversation with your clinician. It cannot determine whether this approach fits your medical profile.
If you are considering next steps, use this information as a foundation, then bring it to a qualified prescriber who can apply it to your situation.
Questions to Ask Your Clinician About How SPRAVATO Works
Mechanism-Focused Tracking: What to Write Down Between Visits
A simple log can make follow-ups more accurate. Keep it brief, and add enough context to help your clinician see patterns.
Patterns matter more than any single day. Bring your notes to your clinician so you can interpret changes together.
FAQ: Mechanism and Oversight Basics
How fast might SPRAVATO begin working?
Some people notice changes within hours or days, while others need more time. Rapid describes a possible timeline, not a promise. Your clinician will track changes across sessions and weeks.
Why might multiple sessions be used?
The mechanism involves synaptic signaling and plasticity processes that can evolve. Clinicians also watch for stability, not just a brief shift after one dose.
Why is clinician oversight required?
Monitoring is necessary because acute effects may include dissociation, sedation-like symptoms and changes in blood pressure. Oversight supports safety during the period when the medication is most active.
How is this different from a traditional antidepressant?
Many antidepressants begin with serotonin or norepinephrine signaling. Esketamine engages NMDA receptors and shifts glutamate-AMPA receptor signaling, which may alter synaptic function on a different timescale.
Does the mechanism mean my brain is being rewired?
Neuroplasticity means the brain can adapt and strengthen connections. It does not mean your identity changes overnight. The goal is improved flexibility in circuits tied to mood and cognition, supported by therapy and daily habits.
If you have made it this far, you have already done something hard: you stayed with the details while carrying a heavy question. The best current model is a sequence of NMDA modulation leading to changes in glutamate, then AMPA activity, then BDNF-related signaling that supports neuroplasticity. Bring that chain to your clinician, along with your concerns, and ask again in your own words: how does esketamine work for someone like you?
